Biopharma SHAKTI, announced in the Union Budget 2026, aims to strengthen domestic manufacturing of biologics and biosimilars while promoting a transition towards non-animal testing methods. The initiative seeks to enhance innovation and reduce dependence on imports in the pharmaceutical sector.
Biologics are advanced medicines derived from living organisms, consisting of complex proteins used for targeted treatment of diseases like cancer, diabetes and autoimmune disorders. Unlike conventional drugs, they act on specific biological pathways, enabling more precise and effective therapies.
APSC Relevance: Important for science and technology, pharmaceutical sector and healthcare innovation.
Course Purchase Query 